EEG resting-state gamma power as a potential biomarker of excitation / inhibition imbalance in autism: Evidence from the Autism Biomarkers Consortium for Clinical Trials
EEG resting-state gamma power as a potential biomarker of excitation / inhibition imbalance in autism: Evidence from the Autism Biomarkers Consortium for Clinical Trials. // European Neuropsychopharmacology. – URL: https://www.sciencedirect.com/science/article/pii/S0924977X26011053?dgcid=rss_sd_all
EEG resting-state gamma power as a potential biomarker of excitation / inhibition imbalance in autism: Evidence from the Autism Biomarkers Consortium for Clinical Trials. European Neuropsychopharmacology. https://www.sciencedirect.com/science/article/pii/S0924977X26011053?dgcid=rss_sd_all
“EEG resting-state gamma power as a potential biomarker of excitation / inhibition imbalance in autism: Evidence from the Autism Biomarkers Consortium for Clinical Trials.” European Neuropsychopharmacology.
@article{article45550,
title = {EEG resting-state gamma power as a potential biomarker of excitation / inhibition imbalance in autism: Evidence from the Autism Biomarkers Consortium for Clinical Trials},
journal = {European Neuropsychopharmacology},
url = {https://www.sciencedirect.com/science/article/pii/S0924977X26011053?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...